Heparin
- Generic Name
- Heparin
- Brand Names
- Heparin Leo
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- T2410KM04A
- Background
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...
- Indication
Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...
- Associated Conditions
- Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
- Associated Therapies
- Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices
Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04925167
- Locations
- 🇨🇳
Bing Sun, Beijing, Beijing, China
Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2023-03-21
- Target Recruit Count
- 100
- Registration Number
- NCT04861922
- Locations
- 🇨🇳
The third Xiangya Hospital, Central South University, Changsha, Hunan, China
Nebulized Heparin for COVID19-associated Acute Respiratory Failure
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Brittany Bissell
- Target Recruit Count
- 2
- Registration Number
- NCT04842292
- Locations
- 🇺🇸
UK Healthcare, Lexington, Kentucky, United States
Comparison of Effectiveness and Complications of Catheter Lock Solutions in Non-tunneled Hemodialysis Catheters
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Zonguldak Ataturk State Hospital
- Target Recruit Count
- 441
- Registration Number
- NCT04772209
- Locations
- 🇹🇷
Cumhuriyet University Hospital, Sivas, TN, Turkey
🇹🇷Zonguldak ataturk state hospital, Zonguldak, TN, Turkey
Continuous Heparin Infusion to Prevent Catheter-related Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT04767113
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Enriched Heparin Anti COVID-19 Trial
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- UPECLIN HC FM Botucatu Unesp
- Target Recruit Count
- 27
- Registration Number
- NCT04743011
- Locations
- 🇧🇷
Hospital das Clinicas de Boucatu, Botucatu, Sao Paulo, Brazil
🇧🇷School of Medicine at Botucatu- Paulista State University- UNESP, São Paulo, Brazil, Botucatu, SP, Brazil
Nebulized Heparin for the Treatment of COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Frederick Health
- Target Recruit Count
- 50
- Registration Number
- NCT04723563
- Locations
- 🇺🇸
Frederick Health Hospital, Frederick, Maryland, United States
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- ARCA Biopharma, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT04655586
- Locations
- 🇺🇸
ARCA Investigational Site #120, Tucson, Arizona, United States
🇦🇷ARCA Investigational Site #112, Rosario, Sante Fe, Argentina
🇦🇷ARCA Investigational Site #127, San Nicolás, Buenos Aires, Argentina
Inhaled Heparin for Hospitalised COVID-19 Patients
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Australian National University
- Target Recruit Count
- 485
- Registration Number
- NCT04635241
- Locations
- 🇪🇬
15th May hospital, Cairo, Egypt
🇦🇷San Camilo Clinic, Buenos Aires, Argentina
🇮🇩RSUD Dr Moewardi, Surakarta, Indonesia
Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
- Target Recruit Count
- 1988
- Registration Number
- NCT04561648
- Locations
- 🇲🇽
Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Tlalpan, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.